CD4 and inflammatory breast carcinoma: Also, the Foxp3+ (Treg) cell subset ranked as the second highest proportion of CD4+ T cells in IBC patients representing 23.1% (with an average 16.71 ± 4.06%, n = 4), whereas it ranked as the lowest proportion of CD4+ T cells in non-IBC patients representing 14.56% (with an average 16.15 ± 2.84%, n = 10), although there was no significant difference between non-IBC and IBC patients (Fig 1, Table 2).